Filing Details
- Accession Number:
- 0001479290-23-000074
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-05-16 20:29:16
- Reporting Period:
- 2022-02-02
- Accepted Time:
- 2023-05-16 20:29:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1479290 | Revance Therapeutics Inc. | RVNC | Pharmaceutical Preparations (2834) | 770551645 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1529196 | J Mark Foley | C/O Revance Therapeutics, Inc. 1222 Demonbreun Street, 20Th Floor Nashville TN 37203 | Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-02-02 | 175,649 | $0.00 | 993,659 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2023-05-15 | 70,447 | $34.55 | 923,212 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 110,913 | Indirect | See footnote |
Footnotes
- Represents settlement of a performance-based restricted stock unit ("PSU") granted on February 2, 2022. On May 12, 2023, the Issuer's Compensation Committee certified 100% of the PSUs eligible to vest based on pre-established criteria related to the price of the Issuer's common stock.
- Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.02 to $34.55. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.
Billionaire Hedge Funds
